Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Major Depressive Disorder, single or recurrent episode, according to DSM-IV criteria~* HAM-D17 total score \> or = 22 at Screening and Baseline~* CGI-Severity score \> or = 4 at Screening and Baseline~* Only patients who complete the core protocol are eligible to participate in the Open-Label Extension Phase~Exclusion Criteria:~* History of bipolar disorder (I or II), schizophrenia, schizoaffective disorder, eating disorder, or obsessive compulsive disorder~* Any current Axis I disorder other than major depressive disorder which is the focus of treatment~* Substance or alcohol abuse in the last 30 days, dependence in the last 6 months~* Concomitant psychotropic medication, including herbal preparations and melatonin~* Psychotherapy of any type~* Female patients of childbearing potential who are not using effective contraception~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).